Enpro (NPO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Board of directors and corporate governance
Adele M. Gulfo, a current director standing for re-election, was elected to the board of NewAmsterdam Pharma Company N.V. on April 17, 2025.
The supplemental proxy material updates Ms. Gulfo's biography for the 2025 Annual Meeting of Shareholders scheduled for April 30, 2025.
Voting matters and shareholder proposals
Shareholders will vote on the re-election of directors, including Adele M. Gulfo, at the 2025 Annual Meeting on April 30, 2025.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Enpro
- Strong 2025 results and 2026 growth outlook driven by high-margin tech focus and strategic acquisitions.NPO
Investor presentation18 Feb 2026 - Strong 2025 growth and margin expansion set the stage for robust 2026 performance.NPOQ4 202518 Feb 2026
- Adjusted EBITDA rose 14% to $74.0M as Sealing Technologies offset semiconductor weakness.NPOQ2 20242 Feb 2026
- Q3 2024 sales and margins rose, but guidance was cut on semiconductor and OEM weakness.NPOQ3 202416 Jan 2026
- Portfolio transformation and operational excellence drive strong margins and growth outlook.NPOSidoti Small-Cap Virtual Investor Conference11 Jan 2026
- Adjusted EBITDA rose 7.1% in 2024, with 2025 guidance signaling further growth.NPOQ4 202423 Dec 2025
- Accelerating profitable growth with 30%+ margins and strategic expansion in technology sectors.NPOGabelli Funds 35th Annual Pump, Valve & Water Symposium23 Dec 2025
- Proxy covers director elections, executive pay, equity plan, auditor, and ESG priorities.NPOProxy Filing1 Dec 2025
- Director Ronald C. Keating joins Hayward Holdings' board; biography updated for 2025 vote.NPOProxy Filing1 Dec 2025